Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
ACET Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Adicet Bio, Inc.NASDAQ: ACET
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$22.35M, compared with -$11.89M a year earlier.
Context
- Net debt amounted to 13.2% of total assets at the end of Q1 FY2026, up 7.0 pp from a year earlier.
- Net debt grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -88.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (24.18M) USD
- Year-over-year change
- +38.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.18M) | +38.4% |
| FY2024 | 2024-12-31 | (39.26M) | +71.7% |
| FY2023 | 2023-12-31 | (138.79M) | +41.3% |
| FY2022 | 2022-12-31 | (236.63M) | +7.8% |
| FY2021 | 2021-12-31 | (256.6M) | — |
Net Debt vs competitors
How ACET compares with its peers on the latest reported figures
- ACET's Mar 2026 net debt of -$22.35M is the 4th highest of the 8 companies compared; the peer median is -$31.65M.
- Its year-over-year change of -88.0% is the 6th highest of 8, against a peer median of -2.3%.
- Net debt amounts to 13.2% of total assets for ACET, versus a peer median of 84.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$5.78M | -302.8% | — | 48.6% | |
| Mar 2026 | -$15.87M | -87.5% | — | 84.7% | |
| Jun 2026 | -$21.99M | +45.6% | — | 91.0% | |
| Mar 2026 | -$22.35M | -88.0% | — | 13.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | -$31.65M | +11.2% | — | 29.4% |
| Mar 2026 | -$35.52M | +37.8% | — | 17.6% | |
| Dec 2025 | -$68.26M | -2.3% | — | 87.2% | |
| Mar 2026 | -$186.21M | -1297.0% | — | 98.1% | |
| Peer median (excluding ACET) | -$31.65M | -2.3% | — | 84.7% | |
Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 277.54M | 257.66M | 159.71M | 56.5M | 38.92M |
| Short-term Investments | 0 | 0 | 0 | 119.81M | 119.61M |
| Net Receivables | 214K | 435K | 0 | 0 | 342K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2K | 336K | 457K | 474K | 320K |
| Total Current Assets | 282.44M | 261.04M | 162.27M | 180.14M | 160.93M |
| Property, Plant & Equipment (Net) | 35M | 48.98M | 44.2M | 36.75M | 28.48M |
| Goodwill | 19.46M | 19.46M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.87M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.04M | 1.21M | 822K | 3.33M | 76K |
| Total Non-current Assets | 56.5M | 69.65M | 45.02M | 40.08M | 31.43M |
| Total Assets | 338.94M | 330.69M | 207.3M | 220.22M | 192.36M |
| Account Payables | 3.26M | 4.4M | 2.63M | 4.83M | 4.74M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.81M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.02M | 5.7M | 6.93M | 7.11M | 5.63M |
| Total Current Liabilities | 16.32M | 19.71M | 19.29M | 19.39M | 21.53M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 115K | 114K | 130K | 116K | 62K |
| Total Non-current Liabilities | 19.49M | 18.65M | 17.83M | 14.22M | 11.61M |
| Total Liabilities | 35.81M | 38.35M | 37.12M | 33.61M | 33.15M |
| Common Stock | 4K | 4K | 4K | 8K | 10K |
| Retained Earnings | (168.32M) | (238.11M) | (380.77M) | (497.89M) | (614.7M) |
| Accumulated OCI | 0 | 0 | 0 | 16K | 102K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 303.13M | 292.34M | 170.18M | 186.61M | 159.21M |
| Total Debt | 20.94M | 21.02M | 20.92M | 17.23M | 14.74M |
| Net Debt | (256.6M) | (236.63M) | (138.79M) | (39.26M) | (24.18M) |
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.